Skip to main content

Advertisement

You are viewing the new article page. Let us know what you think. Return to old version

Occipital anaplastic oligodendroglioma with multiple organ metastases after a short clinical course: a case report and literature review

Diagnostic Pathologyvolume 9, Article number: 17 (2014) | Download Citation

Abstract

Background

It is generally believed that malignant gliomas never metastasize outside the central nervous system (CNS). However, the notion that oligodendrogliomas (OGDs) cells cannot spread outside CNS is being challenged.

Methods

We described in detail the clinical story of one patient with anaplastic OGD, which metastasized to lymph nodes, bone marrowand bones Genetic analyses included detection of 1p and 19q chromosomal arms, methylation status of MGMT promoter, and PTEN exon mutations. A search of worldwide literature was conducted for reports of metastatic OGDs using NCBI-PubMed, with the keywords “extracranial”, “extraneural”, “oligodendroglioma”, “oligodendrogliomas”, “metastatic”, “metastasis”, and “metastases”, in different combinations.

Results

An open biopsy of the infiltrated bones in our patient revealed that malignant cells had replaced the patient’s marrow. Moreover, the diagnosis of multiple-organ metastases of anaplastic OGD was confirmed based on immunohistochemical staining. Genetic analyses showed that the tumors originated from previously resected brain lesions. None of the lesions had 1p and 19q deletions, but hypermethylation of MGMT promoter, and the G → A transversion at codon 234 of PTEN exon 2 were detected. Literatures review yielded 60 reports of metastatic OGDs from 1951 to the present, which with our patient makes 61 cases. Concerning these 61 patients, there were 110 infiltrated sites correlated closely with primary OGDs. The most frequent metastatic sites were bone and bone marrow (n = 47; 42.7%), lymph nodes (n = 22; 20.0%), liver (n = 7; 6.4%), scalp (n = 6; 5.5%), lung (n = 6; 5.5%), pleura (n = 4; 3.6%), chest wall (n = 3; 2.7%), iliopsoas muscle (n = 2; 1.8%), soft tissue (n = 2; 1.8%), and parotid gland (n = 2; 1.8%).

Conclusions

Extracranial metastases in anaplastic OGD are very rare but they do occur; bone and bone marrow may be the most common sites. Detection of certain molecular markers such as deletion of 1p and 19q chromosomal arms, hypermethylation of MGMT promoter, and characteristic PTEN exon mutations may help differentiate subtypes which are more prone to extracranial metastases.

Virtual slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/8749838611478560.

Background

It has been widely believed by neurosurgeons and neurooncologists that malignant gliomas never metastasize outside the central nervous system (CNS) [1]. However, this notion has gradually proved incorrect. A review of 8000 tumors involving the CNS found only 35 cases of extracranial metastasis, including one oligodendroglioma (OGD) [2]. Liwnicz and Rubinstein [3] analyzed 116 cases in the literature and found that the most common metastasizing tumor type was glioblastoma multiforme (41.4%) followed by medulloblastoma (26.7%), ependymoma (16.4%), and astrocytoma (10.3%). and OGD (5.25%) was the least common tumor type to metastasize [3, 4].

OGD is an uncommon diffuse glial tumor of central neuroepithelial origin, accounting for ~4.2% of all primary brain tumors. It has been mostly identified in adults, with the highest incidence occurring in the fifth and sixth decades of life, although it has also been reported in children and adolescents [5]. Various forms of combination therapy administered as comprehensive treatment have improved the survival of patients with OGD or mixed oligoastrocytoma [6].

Herein, we report a case of anaplastic oligodendroglioma (AO) that metastasized to multiple lymph nodes, bone marrow, and bones, including the bilateral iliac bones, the right acetabulum, and multi-vertebral bodies.

Case presentation

A 45-year-old male who initially presented with a short history of headache and vomiting was admitted to our hospital in September 2011. No focal neurological deficit was found on admission. Magnetic resonance imaging (MRI) showed a left solid occipital tumor with mild contrast enhancing (Figure 1A,B,C). On 15 September 2011 he underwent a left solid occipital craniotomy with gross total resection confirmed by subsequent MRI scans (Figure 1D,E,F). The mass was yellow and friable. It was neither hemorrhagic nor necrotic. The tumor margin was ill defined. Photomicrographs of the resected tumor showed that there were higher cell densities, densely packed round cells with perinuclear haloes, microscopically round-to-oblong cells with hyperchromatism and pleomorphism (Figure 2A-D), clusters of capillary or plexiform capillaries (Figure 2E,F), and obvious false fence structure-shaped necrosis (Figure 2G,H). In addition, the irregular mitosis densities were higher. A diagnosis was made of AO, WHO (World Health Organization) grade III [7, 8]. During the subsequent 6 months, he was given 4 cycles of adjuvant chemotherapy with temozolomide (TMZ; Schering, NJ), a standard regimen [9] of 150–200 mg · m-2 · d-1 for 5 days, repeated every 28 days.

Figure 1
figure1

Representative axial MR images with gadolinium, taken on initial admission. (A) T1-weighted MR image (T1WI); (B) Contrast-enhanced T1WI and (C) T2-weighted MR image (T2WI) showing a left occipital tumor with mild contrast enhancing; (D) at one month follow up, T1WI; (E) contrast-enhanced T1WI and (F) T2WI showing no apparent enhanced lesion; (G) 8 months later after the first surgery, T1WI; (H) contrast-enhanced T1WI and (I) T2WI showing marked enhanced mass on the cavity and recurrence; (J) 48 h after the second surgery, T1WI; (K) contrast-enhanced T1WI, and (L) T2WI showing no apparent enhanced lesion; (M) 8 months later after combination radiotherapy and chemotherapy, T1WI; (N) contrast-enhanced T1WI and (O) T2WI showing marked enhanced mass of the wall in the posterior portion of the removal cavity and left temporal areas, and recurrence of the enhanced tumor. (P, Q) 8 months later after combination radiotherapy and chemotherapy, sagittal spinal contrast-enhanced T1WI after gadolinium infusion showing high-intensity mass lesion in (P) T7, T10, and T12 vertebral bodies (arrowheads) and (Q) T12, L2, L3, L5, and S1 vertebral bodies (arrows).

Full size image
Figure 2
figure2

Representative photomicrographs of the tumor specimens. Higher cell densities (A, B; 100×, 200×, respectively, H & E) with perinuclear haloes (C; 200×, H & E; arrows), and microscopically round-to-oblong cells with hyperchromatism and pleomorphism (D; 400×, H & E), are compatible with AO. (E, F) Clusters of capillary or plexiform capillaries (arrows), and the irregular mitosis densities were higher (100×, 200×, respectively, H & E). (G, H) Obvious false fence structure (thick arrows)-shaped necrosis (slim arrows; 100×, 200×, respectively, H & E). (I, J) After the right iliac bone marrow needle biopsy, cells in the bone marrow specimen from the patient were small and round with a thin rim of eosinophilic cytoplasm (400×, H & E).

Full size image

A repeated left occipital tumor resection was performed 8 months later (Figure 1G-L). Pathology also showed AO WHO grade III, with similar histology. Subsequently, irradiation therapy concomitant with TMZ, 75 mg · m-2 · d-1 for 42 days, was given and then 3 cycles of adjuvant chemotherapy with a dose-intensive regimen of TMZ [10] of 75 mg · m-2 · d-1 for 21 days, repeated every 28 days. The patient experienced no significant hematological toxicity, but he came to have difficulties in understanding and remembering.

In October 2012, 5 months after the final occipital resection, he presented with a 3-week history of lumbar and right hipbone pain, and was hospitalized again in November 2012. Regretfully, brain MRI showed evident progression of the intracranial lesion (Figure 1M-O). There was a solid enhancing lesion of high signal intensity on T2-weighted MR images, and low-intensity signals in the temporal area. The new lesion was thought to be a recurrent tumor with malignant transformation (Figure 1M-O). MR images of the spine showed diffuse patchy areas of increased signal intensity and abnormal enhancement of the T7, T10, T12, L2, L3, L5, and S1 vertebral bodies (Figure 1P,Q).

Subsequent bone scintigraphy and positron emission tomography (PET)-computed tomography (CT) scans revealed more multifocal invasion. A whole body 99mTc-methylene diphosphonate bone scan showed hyper-activity in the right iliac bone and the tenth and twelfth thoracic vertebral bodies (Figure 3). PET-CT scans also showed multifocal invasion of the bilateral iliac bones, the right acetabulum, the right femoral neck and the C4, T7, T10, T11, T12, L2, L3, and S1 vertebral bodies (Figure 4A,B), the lymph nodes at the left side of the eleventh thoracic vertebral body (Figure 4C) and the right supraclavicular region (Figure 4D).

Figure 3
figure3

Representative emission computed tomography scans. (A) anterior scans, and (B) posterior scans, showed a hypermetabolically abnormal uptake at the right iliac bone (arrowheads) and T10, and T12 vertebral bodies (arrows).

Full size image
Figure 4
figure4

Representative whole body PET-CT scans. (A) and (B) Multiple foci of increased 18 F-fluoro-2-deoxyglucose (FDG) uptake at the bilateral iliac bones, C4, T7, T11, T10, T12, L2, L3, S1 vertebral bodies and the right acetabulum; (C) Focus of increased 18 F-FDG uptake at the lymph node near the left side of the T11 vertebral body (arrows); (D) Focus of increased 18 F-FDG uptake at the lymph node of the right supraclavicular region (arrows).

Full size image

A bone marrow smear of the right iliac bone showed no plasmacytoma cells (Figure 5). An open biopsy of the infiltrated right iliac bone revealed the replacement of the patient’s marrow by malignant cells, which exhibited nuclear pleomorphism (Figure 2I,J). The confirmed diagnosis of AO metastasis to bone marrow was based on immunohistochemical staining. We simultaneously reviewed and performed the tumor cell identification in the bone marrow spaces as well as in the previously primary AO in the brain. They were all strongly positive for isocitrate dehydrogenase-1 (IDH1; Figure 6A,B) and Ki-67, with proliferation index >80% (Figure 6C). They were also all positive for the glial fibrillary acidic protein (GFAP) marker (Figure 6D), which is positive in glial, Schwannian, and ependymal tumors (all neural tumors), and for the marker oligodendrocyte transcription factor (Oligo-2; Figure 6E). These findings supported the CNS origin of the metastatic cells. Further findings were all negative for other pertinent immunohistochemical stains: epithelial membrane antigen (EMA), O6– methylguanine-DNA methyltransferase (MGMT) and vimentin (Figure 6F,G,H, respectively). Multiple outside pathologists confirmed this diagnosis. After discussion with the patient and his family, he was admitted to the family ward and supportive care was administered until his death on 19 January 2013.

Figure 5
figure5

Representative scans of bone marrow smear. (A, B) No plasmocytoma cells were found (100× and 1000×, respectively).

Full size image
Figure 6
figure6

Representative immunochemical markers in tumor specimens. (A, B) Positive reaction for IDH1 (100×, 200×, respectively). (C) Positive reaction for Ki-67, with proliferating index >80% (200×). (D, E) Tumor cells were positive for GFAP and Oligo-2, respectively (200×). (F, G, H) showed the tumor cells were negative for EMA, MGMT, and vimentin, respectively (200×).

Full size image

Materials and methods

Tissue samples

We collected and analyzed both the bone marrow from the above mentioned open biopsy and the brain tumor tissues resected in the first and second craniotomy. The Human Research Committee of the Fourth Military Medical University approved the use of human tissues, in accordance with the Approval of Research Involving Human Subjects. The patient’s custodians provided informed written consent. All specimens were handled and made anonymous in accordance with ethical and legal standards.

DNA extraction

The bone marrow from the biopsy was decalcified using ultrasonic decalcification with ethylenediaminetetraacetic acid (EDTA) as described previously [11] and paraffin embedded. DNA was extracted from the tumor tissues as previously described [12, 13]. In brief, DNA was isolated by sodium dodecyl sulfate/proteinase K treatment, phenol–chloroform extraction, and ethanol precipitation and then dissolved and stored in 1× Tris-EDTA (TE) buffer. DNA concentration was measured at optical density 260 (OD260), and purity was verified by OD260/OD280 ≈ 1.8.

Fluorescent in situ hybridization (FISH) assay

Sections from the brain tumors and metastatic lesions were evaluated with routine hematoxylin-eosin (H & E) staining. FISH assays were also performed for molecular characterization. Both the brain tumors and the metastatic lesions were analyzed to perform dual-color FISH assay as previously published [14]. Briefly, paired probes for 1p36/1q25-q31 and 19q13/19p12 (Abbott Molecular) were prepared [14]. Green and red fluorescent signals were enumerated under a Leica microscope with appropriate filters. For each hybridization, a minimum of 40 non-overlapping nuclei were assessed for numbers of green and red signals, counted separately by two individuals.

MGMT promoter methylation status

DNA from the tumor tissues was analyzed by performing a methylation-specific polymerase chain reaction (MS-PCR) assay, as previously published [15], to detect the status of the MGMT promoter.

PCR single-strand conformation polymorphism (PCR-SSCP) and DNA sequencing for phosphatase and tensin homologue (PTEN) deleted on chromosome ten exons

PCR–SSCP assay was applied to elucidate the mutations in exons 1–9 of the PTEN gene (Table 1) [16–18]. PCR amplification was carried out in a final volume of 25 μL containing 50 ng DNA, 2.5 μL of 10× PCR buffer, 1.5 mmol/L MgCl2, 10 pmol/L of each primer, 2.5 mmol/L of each dNTP, and 1 U Taq DNA polymerase. The amplification conditions were: an initial incubation at 95°C for 8 min; 35 cycles at 95°C for 30 s, 51–57°C for 45 s for each primer specific to the PTEN exons (Table 1), and 72°C for 30 s; with a final extension at 72°C for 7 min. PCR products were resolved in 2% agarose gels stained with ethidium bromide with a 100-bp DNA ladder as a standard reference, and electrophoresed for 30 min at 100 V.

Table 1 PTEN primers used for single-strand conformation polymorphism (SSCP) analysis
Full size table

SSCP analyses of all PTEN exons were conducted systematically on the PCR products. Equal volumes (7 μL) of the PCR products and loading buffer (95% formamide, 20 mM EDTA, 0.05% bromphenol blue, and 0.05% xylene cyanol) were mixed and centrifuged for 15 s, heat-denatured at 95°C for 7 min, snap-chilled on ice for 10 min, and resolved through an 8% non-denaturing polyacrylamide gel (acrylamide to bisacrylamide, 29:1) containing 50 mM Tris-borate (pH 7.5) and 2.5 mM EDTA, and electrophoresed with 1× tris-borate-EDTA buffer for 16 h at 14°C at a voltage of 100 V. Silver staining was performed as previously described [19].

According to the PCR-SSCP results of genomic DNA, the present sample was considered PCR-SSCP positive based on the evident difference in the single strand strip number and electrophoresis transference location [20]. Genomic DNA from the positive PCR-SSCP sample was amplified again in a 40-μL reaction system for bidirectional DNA sequencing. The amplified PCR products were sequenced with an ABI PRISM 310 dye terminator cycle sequencing ready reaction kit. The results were compared using the GenBank database.

Results

FISH analysis

None of the tumors from the resected brain lesions or the metastatic lesions had the 1p (Figure 7A) or 19q deletions (Figure 7B). We were satisfied that, although the bone marrow from the biopsy was decalcified via ultrasonic decalcification and EDTA, the metastatic lesions remained informative.

Figure 7
figure7

Representative FISH images from the right iliac bone. Some signals are missing due to nuclear truncation. (A) No 1p deletion, with 2 red (1p36, arrows) and 2 green (1q25-q31, arrowheads) signals in scattered nuclei. (B) No 19q deletion with 2 red (19q13, arrows) and 2 green (19p12, arrowheads) signals in scattered nuclei.

Full size image

Methylation status of the MGMT promoter

The MSP-PCR assays of the tumors from the primary brain lesions and autopsied metastasized tissues all showed the methylated MGMT promoter (Figure 8), and the result from the corresponding samples was nearly identical.

Figure 8
figure8

Representative MSP-PCR for methylated MGMT promoter. NTC, non DNA template control; +, methylated; –, unmethylated; M, DNA marker; the upper, middle, and lower bands are 140, 120, 100, and 80 bp, respectively.

Full size image

PTEN mutation

The case was considered PCR-SSCP-positive, and genomic DNA from the samples was amplified for bidirectional DNA sequencing. Compared with the sequences in the GenBank database, the sequencing data of the patient showed a transversion, “A” in place of “G” at codon 234 of exon 2. This was thought to be a likely single nucleotide polymorphism (Figure 9). No mutation was detected in the other PTEN exons.

Figure 9
figure9

Representative sequencing data showing the G → A transversion at codon 234 (arrows) of exon 2 in PTEN of the patient. Blue, primer; red, exon 2; purple, the transversion of A, showing the polymorphism.

Full size image

Discussion

Extraneural metastases from primary brain tumors are rare [21] for reasons that remain obscure. Proposed initial theories generally lack credibility among neurosurgeons and neurooncologists; these include collapse of thin-walled cerebral veins, the inability of neural tissue to grow outside the CNS, and the lack of lymphatics in the brain [22]. More accepted is the theory that because brain tumors present earlier, there is less time for metastases to develop [21]. Another theory suggests that the intracerebral environment is not sufficiently hostile to select out metastatic clones. There is relatively little connective tissue stroma in the brain compared with the rest of the body. It has also been proposed that clones are not selected for the ability to invade fibrous connective tissue and are thus not suited to invade extracranial tissues [23]. The role of the blood–brain barrier is also uncertain, albeit it does seem to have a limited role in metastasis.

Despite the above theories, glioma does metastasize outside the CNS, and most cases of extraneural metastasis (nearly 96%) have occurred after surgical excision of the primary tumor [24]. The most common glioma to metastasize is glioblastoma multiforme, followed by medulloblastoma and ependymoma [4], while OGD metastasizes very rarely.

OGD is such a diffuse glial tumor. Extracranial metastasis of the primary intracranial neoplasm is infrequent generally, and it seemed to usually happen only in the setting of prior neurosurgical resection [25]. OGDs are characterized by multiple recurrences [25], extraneural spread is unusual, and distant skeletal metastases are particularly infrequent. We therefore undertook a worldwide literature review to investigate further the incidence of extraneural metastases. This yielded 60 previously reported metastatic OGDs from 1951 to the present, and our patient makes 61 (Table 2). The review was performed using NCBI-PubMed with the keywords “extracranial”, “extraneural”, “oligodendroglioma”, “oligodendrogliomas”, “metastatic”, “metastasis”, and “metastases” in different combinations. We also reviewed the bibliography of the subsequently selected articles.

Table 2 Review from the literature of 61 reported patients with oligodendroglioma with metastases outside the CNS
Full size table

Of the 61 reported metastatic OGDs, 33 (54.1%) were male, 17 (27.9%) were female, and in the remaining cases 18.0% gender was not reported (Table 3). Ten (16.4%) patients were Asian, 30 (49.2%) were European, 18 (29.5%) were American or Canadian, and for the remaining 3 (4.9%) the ethnicities were unreported. There were 110 infiltrated sites correlated closely with primary OGDs. The most frequent metastatic site was bone and bone marrow (n = 47; 42.7%) followed by lymph nodes (n = 22; 20.0%), liver (n = 7; 6.4%), scalp (n = 6; 5.5%), lung (n = 6; 5.5%), pleura (n = 4; 3.6%), chest wall (n = 3; 2.7%), iliopsoas muscle (n = 2; 1.8%), soft tissue (n = 2; 1.8%), parotid gland (n = 2; 1.8%), and adrenal gland, spleen, thoracic wall, pancreas, dorsal root ganglia, abdomen, spinal dura mater, breast, and thymus gland with one lesion each (n = 1; 0.9%).

Table 3 Clinical features of 61 patients with extracranial metastatic oligodendrogliomas
Full size table

The review indicated that bone and bone marrow are the most common sites metastasizing from OGDs. In our present case, systematic examination found multiple extracranial metastases, including the vertebrae, lymph nodes, bilateral iliac bones, and right acetabulum. Metastases in these sites suggest that tumor cells were delivered via the blood vessels and lymphatic system.

Primary neoplasm in the brain is generally considered to spread in any of three ways: seeding through the cerebral fluid pathway, local invasion, or spreading remotely through lymphatic and blood vessels [68]. It is widely accepted that the brain and spinal cord contain no lymphatic pathway. However, as the tumor cells infiltrate the dura mater, extracranial metastasis by way of the lymphatic system becomes possible, and could especially happen after craniotomy. Surgical procedures can elevate the risk of metastasis outside the nervous system by way of the lymphatic system as well as the blood vessel.

Extraneural metastasis is considered correlated with multiple craniotomies, shunt surgery, and long-term survival [39, 69, 70]. Extracranial metastasis without previous surgical intervention is infrequent; among 282 reported cases of glioma with metastases outside the CNS only 24 (8.5%) were spontaneous [71]. Most cases of extracranial metastasis occur after craniotomy. Shunt surgery is responsible for seeding tumor cells by way of cerebrospinal fluid to outside spaces [72]. Prolonged survival might also raise the risk of extracranial metastases. Thus, in our present case, craniotomy could be considered an influencing factor in extracranial metastasis.

The median age of the 60 patients found through the literature review was 40.0 years (range 3.5-73.0 y; Table 2). The overall survival ranged from 3–288 months, with a median of 38 months. These data are consistent with the recent reports of AOs [57, 63]. The survival time of our patient was relatively shorter than the median, although he was given the standard regimen recommended by the National Comprehensive Cancer Net (NCCN) guidelines [73]. His shorter survival and poor prognosis may be due, firstly, to the presence of 1p/19q, which may have adversely influenced the success of the recommended comprehensive therapy, as combined deletion of the 1p and 19q chromosomal arms is expected in OGD [74]. Molecular studies have revealed that deletions of chromosome 1p and 19q are usually associated with longer survival in OGD, as well as a better response to irradiation and chemotherapy. Tumors with such a co-deletion are sensitive to comprehensive therapy, with 90-100% of patients responding [74, 75]. The overall survival for AOs is about 2–3 years for those without the 1p/19q codeletion, compared with 6–7 years in those with 1p/19q loss [76, 77]. For our patient, the previously resected tumors from the brain lesions, as well as the metastatic lesions, all had complete 1p and 19q chromosomes. Thus the lack of deletion of 1p/19q may have led to a shorter survival time under comprehensive therapy.

A second contributing factor toward the poor prognosis of the present case is the presence of the PTEN mutation, which was shown in both brain lesions and extracranial metastases. This may have made the patient more prone to extracranial metastases. PTEN tumor suppressors are located on human chromosome 10q23.3, which contains nine exons and encodes a 47-kD dual-specific protein phospholipid phosphatase with 403 amino acids [17]. PTEN mutations accompany nearly 50% of the cases with a 10q deletion, suggesting that there might be another progression-related target gene in this region [78]. PTEN mutations and 10q deletions are more common in AOs without 1p and 19q losses [79]. Infrequently AOs carry activating mutations in the PIK3CA gene [80]. PTEN mutations have also been studied for their involvement in the pathogenesis of a number of human malignancies, including glioma [80].

Different mutations in the PTEN locus, including frameshifts and missense mutations, have proved to be correlated with human cancers [81, 82]. These could result in early termination of translation and immature gene products, and subsequently lead to complete loss of vigor. In most cases, mutations in PTEN were found to decrease phosphatase activity [19, 83]. In the present study, our patient definitely had a substitution mutation in PTEN at exon 2, which may have made him more prone to extracranial metastases.

It must also be noted that, although our patient underwent a chemotherapy regimen with TMZ, his condition nevertheless deteriorated more rapidly afterward. As known, AOs are chemosensitive neoplasms that respond to combined treatment with lomustine, vincristine and procarbazine (i.e., PCV therapy), with 60-70% of patients responding [84]. Studies have also shown that TMZ, the oral alkylating agent that inhibits DNA replication by methylating nucleotide bases, is active and particularly well tolerated in AO patients [85, 86]. TMZ methylates guanines in DNA at the O6 position, leading to base-pair mismatch. The known O6– methylguanine (O6–MeG) lesion causes DNA double-strand breaks and subsequent cell death through autophagy, apoptosis, or both [87]. MGMT is the DNA repair enzyme that repairs the O6-MeG lesion and is induced either by chemotherapeutic agents or environmental carcinogens. Methylation of the MGMT promoter or high levels of MGMT are thought to be associated with resistance to TMZ [88]. Levin et al. [86] reported that TMZ was active in patients with progressive OGDs, and that a 1p deletion and low MGMT protein expression could contribute to a better response to TMZ treatment. For our patient, results of the MSP-PCR assays of the primary brain lesions and autopsied metastatic tissues all showed the methylated MGMT promoter. However, we regret that although several cycles of chemotherapy of TMZ were given, the patient still deteriorated rapidly and eventually succumbed. The reasons for his failure to respond favorably to TMZ chemotherapy remain to be explored.

Conclusions

In summary, extracranial metastases in AO do occur, although they are very rare. Detection of molecular markers such as combined deletion of the 1p and 19q chromosomal arms, hypermethylation of the MGMT promoter, and PTEN exon mutations may help elucidate which subtypes of AO are more prone to extracranial metastases, which would benefit these patients.

Consent

Written informed consent was obtained from the patient's family for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations

OGD:

Oligodendrogliomas

MRI:

Magnetic resonance imaging

MGMT:

O-6-methylguanine-DNA methyltransferase

PTEN:

Phosphatase and tensin homolog

CNS:

Central nervous system

AO:

Anaplastic oligodendroglioma

WHO:

World Health Organization

PET-CT:

Positron emission tomography-computed tomography

EDTA:

Ethylenediaminetetraacetic acid

IDH1:

Isocitrate dehydrogenase-1

GFAP:

Glial fibrillary acidic protein

EMA:

Epithelial membrane antigen

MS-PCR:

Methylation-specific polymerase chain reaction

PCR-SSCP:

PCR single-strand conformation polymorphism

FISH:

Fluorescent in situ hybridization

NCCN:

National comprehensive cancer net.

References

  1. 1.

    Bailey P, Cushing P: A Classification of the Tumors of the Glioma Group on Histogenetic Basis with Correlated Study of Prognosis. 1926, Philadelphia: J.B. Lippincott, 175-

  2. 2.

    Smith DR, Hardman JM, Earle KM: Metastasizing neuroectodermal tumors of the central nervous system. J Neurosurg. 1969, 31: 50-58. 10.3171/jns.1969.31.1.0050.

  3. 3.

    Liwnicz BH, Rubinstein LJ: The pathways of extraneural spread in metastasizing gliomas: a report of three cases and critical review of the literature. Hum Pathol. 1979, 10: 453-467. 10.1016/S0046-8177(79)80051-9.

  4. 4.

    Han SR, Yoon SW, Yee GT, Choi CY, Lee DJ, Sohn MJ, Chang SH, Whang CJ: Extraneural metastases of anaplastic oligodendroglioma. J Clin Neurosci. 2008, 15: 946-949. 10.1016/j.jocn.2006.09.013.

  5. 5.

    McLendon RE, Bentley RC, Parisi JE, Tien RD, Harrison JC, Tarbell NJ, Billitt AL, Gualtieri RJ, Friedman HS: Malignant supratentorial glial-neuronal neoplasms: report of two cases and review of the literature. Arch Pathol Lab Med. 1997, 121: 485-492.

  6. 6.

    Tatar Z, Thivat E, Planchat E, Gimbergues P, Gadea E, Abrial C, Durando X: Temozolomide and unusual indications: review of literature. Cancer Treat Rev. 2013, 39: 125-135. 10.1016/j.ctrv.2012.06.002.

  7. 7.

    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114: 97-109. 10.1007/s00401-007-0243-4.

  8. 8.

    Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM, Mork S, Graeber MB, Bauserman S, Buckner JC, Burton J, Riepe R, Tazelaar HD, Nascimento AG, Crotty T, Keeney GL, Pemicone P, Altermatt H: Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol. 2001, 60: 248-282.

  9. 9.

    Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO: European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group: effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10: 459-466. 10.1016/S1470-2045(09)70025-7.

  10. 10.

    Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR: Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008, 26: 4189-4199. 10.1200/JCO.2007.11.5964.

  11. 11.

    Reineke T, Jenni B, Abdou MT, Frigerio S, Zubler P, Moch H, Tinguely M: Ultrasonic decalcification offers new perspectives for rapid FISH, DNA, and RT-PCR analysis in bone marrow trephines. Am J Surg Pathol. 2006, 30: 892-896. 10.1097/01.pas.0000213282.20166.13.

  12. 12.

    Mehdi SJ, Alam MS, Batra S, Rizvi MMA: Allelic loss at 6q25–27, the Parkin tumor suppressor gene locus in cervical carcinoma. Med Oncol. 2011, 28: 1520-1526. 10.1007/s12032-010-9633-x.

  13. 13.

    Sambrook J, Russell DW: Molecular cloning: A laboratory manual. 2001, Cold Spring Harbor Lab. Press: Cold Spring Harbor, 3

  14. 14.

    Dong Z, Pang JS, Ng MH, Poon WS, Zhou L, Ng HK: Identification of two contiguous minimally deleted regions on chromosome 1p36.31-p36.32 in oligodendroglial tumors. Br J Cancer. 2004, 91: 1105-1111. 10.1038/sj.bjc.6602093.

  15. 15.

    Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005, 352: 997-1003. 10.1056/NEJMoa043331.

  16. 16.

    Eng C: PTEN: one gene, many syndromes. Hum Mutat. 2003, 22: 183-198. 10.1002/humu.10257.

  17. 17.

    Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Tsuneyama K, Takano Y: Low expression of FHIT and PTEN correlates with malignancy of gastric carcinomas: tissue-array findings. Appl Immunohistochem Mol Morphol. 2007, 15: 432-440. 10.1097/01.pai.0000213127.96590.2d.

  18. 18.

    Ali A, Saluja SS, Hajela K, Mishra PK, Rizvi MA: Mutational and expressional analyses of PTEN gene in colorectal cancer from Northern India. Mol Carcinog. 2013, 10.1002/mc.22001. [Epub ahead of print]

  19. 19.

    Rizvi MA, Shabbir MA, Ali A, Mehdi SJ, Batra S, Mandal AK: Aberrant promoter methylation and inactivation of PTEN gene in cervical carcinoma from Indian population. J Cancer Res Clin Oncol. 2011, 137: 1255-1262. 10.1007/s00432-011-0994-0.

  20. 20.

    Guo CY, Xu XF, Wu JY, Liu SF: PCR–SSCP-DNA sequencing method in detecting PTEN gene mutation and its significance in human gastric cancer. World J Gastroenterol. 2008, 14: 3804-3811. 10.3748/wjg.14.3804.

  21. 21.

    Garner J, Morcos Y, Bari M: Extradural cord compression due to metastatic oligodendroglioma. J Neurooncol. 2002, 58: 71-75. 10.1023/A:1015805329661.

  22. 22.

    Subramanian A, Harris A, Piggott K, Shieff C, Bradford R: Metastasis to and from the central nervous system: the ‘relatively protected site’. Lancet Oncol. 2002, 3: 498-507. 10.1016/S1470-2045(02)00819-7.

  23. 23.

    Al-Ali F, Hendon AJ, Liepman MK, Wisniewski JL, Krinock MJ, Beckman K: Oligodendroglioma metastatic to bone marrow. AJNR Am J Neuroradiol. 2005, 26: 2410-2414.

  24. 24.

    Fayeye O, Sankaran V, Sherlala K, Choksey M: Oligodendroglioma presenting with intradural spinal metastases: an unusual cause of cauda equine syndrome. J Clin Neurosci. 2010, 17: 265-267. 10.1016/j.jocn.2009.05.029.

  25. 25.

    Shaw EG, Scheithauer BW, O’Fallon JR, Tazelaar HD, Davis DH: Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg. 1992, 76: 428-434. 10.3171/jns.1992.76.3.0428.

  26. 26.

    James TGI, Pagel W: Oligodenroglioma with extracranial metastases. Br J Surg. 1951, 39: 56-65. 10.1002/bjs.18003915312.

  27. 27.

    Spataro J, Sacks O: Oligodendroglioma with remote metastases. Case report. J Neurosurg. 1968, 28: 373-379. 10.3171/jns.1968.28.4.0373.

  28. 28.

    Jellinger K, Minauf M, Salzer-Kuntschik M: Oligodendroglioma with extraneural metastases. J Neurol Neurosurg Psychiatry. 1969, 32: 249-253. 10.1136/jnnp.32.3.249.

  29. 29.

    Schuster H, Jellinger K, Gund A, Regele H: Extracranial metastases of anaplastic cerebral gliomas. Acta Neurochir (Wien). 1976, 35: 247-259. 10.1007/BF01406121.

  30. 30.

    Kernohan JW: Oligodendrogliomas. Minckler J (ed) Pathology of the nervous system. 1971, New York: McGraw-Hill Co, 1993–2007, Vol 2

  31. 31.

    Eade OE, Urich H: Metastasising gliomas in young subjects. J Pathol. 1971, 103: 245-256. 10.1002/path.1711030407.

  32. 32.

    Cappalaere P, Clay A, Adenis L, Demaille A, Laine E: Les metastases des tumors cerebrales primitives en dehors du nevraxe: a propos de trios observations. Bull Cancer (Paris). 1972, 59: 235-254.

  33. 33.

    Brander WL, Turner DR: Extracranial metastases from a glioma in the absence of surgical intervention. J Neurol Neurosurg Psychiatry. 1975, 38: 1133-1135. 10.1136/jnnp.38.11.1133.

  34. 34.

    Kummer RV, Volk B, Dorndorf W: Extraneural metastasierendes oligodendrogliom. Arch Psychiatr Nervenkr. 1969, 223: 287-293.

  35. 35.

    Chin HW, Hazel JJ, Kim TH, Webster JH: Oligodendrogliomas. I. A clinical study of cerebral oligodendrogliomas. Cancer. 1980, 45: 1458-1466. 10.1002/1097-0142(19800315)45:6<1458::AID-CNCR2820450627>3.0.CO;2-0.

  36. 36.

    Ordonez NG, Ayala AA, Leavens ME: Extracranial metastases of oligodenroglioma: report of a case and review of the literature. Neurosurgery. 1981, 8: 391-395. 10.1227/00006123-198103000-00012. comments 395–396

  37. 37.

    Nakamura O, Watanabe T, Nomura K, Nakajima T: Diffuse bone marrow metastasis of an anaplastic oligodendroglioma. No Shinkei Geka. 1985, 13: 903-909.

  38. 38.

    Newman HFV, Howard GCV, Reid PM: Metastatic oligodendroglioma presenting as a leukoerythroblastic anaemia. Eur J Surg Onc. 1985, 11: 287-288.

  39. 39.

    Macdonald DR, O’Brien RA, Gilbert JJ, Cairncross JG: Metastatic anaplastic oligodendroglioma. Neurology. 1989, 39: 1593-1596. 10.1212/WNL.39.12.1593.

  40. 40.

    Rolski J, Rzepecki W, Kałuza J, Zemełka T, Zuchowska-Vogelgesang B: A rare case of dissemination of anaplastic oligodendroma outside the central nervous system. Neurol Neurochir Pol. 1993, 27: 93-97.

  41. 41.

    Steininger H, von Streitberg U: Oligodendroglioma with cervical lymph node metastasis. Pathologe. 1993, 14: 386-390.

  42. 42.

    Gerrard GE, Bond MG, Jack AS: Bone marrow infiltration by a parietal lobe grade III oligodendroglioma. Clin Oncol (R Coll Radiol). 1995, 7: 321-322. 10.1016/S0936-6555(05)80543-6.

  43. 43.

    Schröder R, Lorenzen J, Ostertag H, Ortmann M, Hansmann ML: Extraneural metastasis of brain and spinal cord tumors. Report of 2 cases. Pathologe. 1995, 16: 223-229. 10.1007/s002920050095.

  44. 44.

    Monzani V, Rovellini A, Masini B, Cappricci E, Miserocchi G: Metastatic oligodendroglioma. Case report. J Neurol Sci. 1996, 40: 239-241.

  45. 45.

    Dawson TP: Case report. Pancytopenia from a disseminated anaplastic oligodendroglioma. Neuropathol App Neurobiol. 1997, 23: 516-520. 10.1111/j.1365-2990.1997.tb01330.x.

  46. 46.

    Finsterer J, Breiteneder S, Mueller MR, Wogritsch C, Vesely M, Kleinert R, Pendl G, Mamoli B: Pleural and bone marrow metastasis from supratentorial oligoastrocytoma grade III. Oncology. 1998, 55: 345-348. 10.1159/000011875.

  47. 47.

    Anand M, Kumar R, Jain P, Gupta R, Ghosal N, Sharma A, Agarwal A, Sharma MC: Metastatic anaplastic oligodendroglioma simulating acute leukaemia. Acta Cytol. 2003, 47: 467-469. 10.1159/000326552.

  48. 48.

    Giordana MT, Gasverde S, Balteri I: Bone metastasis of oligodendrogliomas: clinical and molecular genetic study. Neuro Oncol. 2002, 4: 38e-

  49. 49.

    Sharma A, Agarwal A, Sharma MC, Anand M, Agarwal S, Raina V: Bone marrow metastasis in anaplastic oligodendroglioma. Int J Clin Pract. 2003, 57: 351-352.

  50. 50.

    Choon A, Roepke JE: Importance of immunohistochemichal staining in metastatic anaplastic oligodendroglioma. Arch Pathol Lab Med. 2004, 128: 489-490.

  51. 51.

    Morrison T, Bilbao JM, Yang G, Perry JR: Bony metastases of anaplastic oligodendroglioma respond to temozolomide. Can J Neurol Sci. 2004, 31: 102-108.

  52. 52.

    Wang M, Murphy KM, Kulesza P, Hatanpaa KJ, Olivi A, Tufaro A, Erozan Y, Westra WH, Burger PC, Berg KD: Molecular diagnosis of metastasizing oligodendroglioma: a case report. J Mol Diagn. 2004, 6: 52-57. 10.1016/S1525-1578(10)60491-6.

  53. 53.

    Merrell R, Nabors LB, Perry A, Palmer CA: 1p/19q chromosome deletions in metastatic oligodendroglioma. J Neurooncol. 2006, 80: 203-207. 10.1007/s11060-006-9179-0.

  54. 54.

    Lee CC, Jiang JS, Chen ET, Yokoo H, Pan YH, Tsai MD: Cytologic diagnosis of a metastatic oligodendroglioma in a pleural effusion. A case report. Acta Cytol. 2006, 50: 542-544. 10.1159/000326011.

  55. 55.

    Bruggers C, White K, Zhou H, Chen Z: Extracranial relapse of an anaplastic oligodendroglioma in an adolescent: case report and review of the literature. J Pediatr Hematol Oncol. 2007, 29: 319-322. 10.1097/MPH.0b013e318054756e.

  56. 56.

    Uzuka T, Kakita A, Inenaga C, Takahashi H, Tanaka R, Takahashi H: Frontal anaplastic oligodendroglioma showing multi-organ metastases after a long clinical course. Case report. Neurol Med Chir (Tokyo). 2007, 47: 174-177. 10.2176/nmc.47.174.

  57. 57.

    Zustovich F, Della Puppa A, Scienza R, Anselmi P, Furlan C, Cartei G: Metastatic oligodendrogliomas: a review of the literature and case report. Acta Neurochir (Wien). 2008, 150: 699-702. 10.1007/s00701-008-1507-z. discussion 702–703

  58. 58.

    Volavsek M, Lamovec J, Popović M: Extraneural metastases of anaplastic oligodendroglial tumors. Pathol Res Pract. 2009, 205: 502-507. 10.1016/j.prp.2008.11.003.

  59. 59.

    Noshita N, Mashiyama S, Fukawa O, Asano S, Watanabe M, Tominaga T: Extracranial metastasis of anaplastic oligodendroglioma with 1p19q loss of heterozygosity–case report. Neurol Med Chir (Tokyo). 2010, 50: 161-164. 10.2176/nmc.50.161.

  60. 60.

    Oshiro S, Komatsu F, Tsugu H, Nabeshima K, Abe H, Ohkawa M, Inoue T: A case of intramedullary cervical metastasis from cerebellar anaplastic oligodendroglioma without typical MR appearance for CSF dissemination. No Shinkei Geka. 2010, 38: 279-285.

  61. 61.

    Krijnen JL, Fleischeur RE, van Berkel M, Westenend PJ: Metastatic oligodendroglioma: a case report and incidence in The Netherlands. Clin Neuropathol. 2010, 29: 141-146. 10.5414/NPP29141.

  62. 62.

    Kural C, Pusat S, Sentürk T, Seçer Hİ, Izci Y: Extracranial metastases of anaplastic oligodendroglioma. J Clin Neurosci. 2011, 18: 136-138. 10.1016/j.jocn.2010.05.028.

  63. 63.

    Wu Y, Liu B, Qu L, Tao H: Extracranial skeletal metastasis in anaplastic oligodendroglioma: case report and review of the literature. J Int Med Res. 2011, 39: 960-967. 10.1177/147323001103900331.

  64. 64.

    Cordiano V, Miserocchi F, Storti M: Bone marrow metastases from anaplastic oligodendroglioma presenting with pancytopenia and hypogammaglobulinemia: a case report. Tumori. 2011, 97: 808-811.

  65. 65.

    Can B, Akpolat I, Meydan D, Üner A, Kandemir B, Söylemezoğlu F: Fine-needle aspiration cytology of metastatic oligodendroglioma: case report and literature review. Acta Cytol. 2012, 56: 97-103. 10.1159/000331769.

  66. 66.

    Alacacioglu A, Unal S, Canpolat S, Yurt A, Oztekin O, Coskun A, Karatas A, Postaci H, Sop G: Breast metastasis of anaplastic oligodendroglioma: a case report. Tumori. 2012, 98: 162e-164e.

  67. 67.

    Greene J, Cadoo K, Ti J, O’Donnell N, Allcutt D, Farrell M, Grogan L: 1p19q co-deleted oligodendroglioma metastatic to bone. Clin Neuropathol. 2013, 32: 139-141. 10.5414/NP300507.

  68. 68.

    Gyepes MT, D’ angio GJ: Extracranial metastases from central nervous system tumors in children and adolescents. Radiology. 1966, 87: 55-63.

  69. 69.

    Carlsen JG, Tietze A, Lassen YA, Rosendal F: Paraplegia due to drop metastases from anaplastic oligodendroglioma. Br J Neurosurg. 2012, 26: 94-95. 10.3109/02688697.2011.578767.

  70. 70.

    Schweitzer T, Vince GH, Herbold C, Roosen K, Tonn JC: Extraneural metastases of primary brain tumors. J Neurooncol. 2001, 53: 107-114. 10.1023/A:1012245115209.

  71. 71.

    Hoffman HJ, Duffner PK: Extraneural metastases of central nervous system tumors. Cancer. 1985, 56: 1778-1782. 10.1002/1097-0142(19851001)56:7+<1778::AID-CNCR2820561309>3.0.CO;2-I.

  72. 72.

    Mechtler LL, Nandigam K: Spinal cord tumors: new views and future directions. Neurol Clin. 2013, 31: 241-268. 10.1016/j.ncl.2012.09.011.

  73. 73.

    NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version1. 2013,http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.

  74. 74.

    Cairncross JG, Ueki K, Zlatescu C, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendroglioma. J Natl Cancer Inst. 1998, 90: 1473-1479. 10.1093/jnci/90.19.1473.

  75. 75.

    Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000, 18: 636-645.

  76. 76.

    Davis FG, McCarthy BJ, Freels S, Kupelian V, Bondy ML: The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer. 1999, 85: 485-491. 10.1002/(SICI)1097-0142(19990115)85:2<485::AID-CNCR29>3.0.CO;2-L.

  77. 77.

    Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, Fischbach AJ, Curran WJ: Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90–06. Int J Radiat Oncol Biol Phys. 1998, 40: 51-55. 10.1016/S0360-3016(97)00485-9.

  78. 78.

    Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE, Fults DW, Velculescu VE, Bigner DD, Yan H: Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res. 2004, 64: 5048-5050. 10.1158/0008-5472.CAN-04-1170.

  79. 79.

    Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN: Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. 2001, 7: 839-845.

  80. 80.

    Yang Y, Shao N, Luo G, Li L, Zheng L, Nilsson-Ehle PXN: Mutations of PTEN gene in gliomas correlate to tumor differentiation and short-term survival rate. Anticancer Res. 2010, 30: 981-985.

  81. 81.

    Wang JY, Huang TJ, Chen FM, Hsieh MC, Lin SR, Hou MF, Hsieh JS: Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in advanced gastric carcinomas. Virchows Arch. 2003, 442: 437-443.

  82. 82.

    Tate G, Suzuki T, Mitsuya T: Mutation of the PTEN gene in a human hepatic angiosarcoma. Cancer Genet Cytogenet. 2007, 178: 160-162. 10.1016/j.cancergencyto.2007.07.017.

  83. 83.

    Rizvi MM, Ali A, Mehdi SJ, Saluja SS, Mishra PK: Association of epigenetic alteration in PTEN gene with colorectal cancer progression among Indian population. Int J Colorectal Dis. 2013, 28: 283-284. 10.1007/s00384-012-1482-y.

  84. 84.

    van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros JM, van der Rijt CC, Vecht CJ, Allgeier A, Gorlia T: European Organization for Research and Treatment of Cancer Brain Tumor Group: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol. 2003, 21: 2525-2528. 10.1200/JCO.2003.12.015.

  85. 85.

    Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, Polivka M, Crinière E, Marie Y, Mokhtari K, Carpentier AF, Laigle F, Simon JM, Cornu P, Broët P, Sanson M, Delattre JY: Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004, 22: 3133-3138. 10.1200/JCO.2004.10.169.

  86. 86.

    Levin N, Lavon I, Zelikovitsh B, Fuchs D, Bokstein F, Fellig Y, Siegal T: Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6- methylguanine DNA methyltransferase protein expression. Cancer. 2006, 106: 1759-1765. 10.1002/cncr.21809.

  87. 87.

    Ziegler DS, Kung AL, Kieran MW: Antiapoptosis mechanisms in malignant gliomas. J Clin Oncol. 2008, 26: 493-500. 10.1200/JCO.2007.13.9717.

  88. 88.

    Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM, Wen PY: Phase II study of protracted daily temozolomide for lowgrade gliomas in adults. Clin Cancer Res. 2009, 15: 330-337. 10.1158/1078-0432.CCR-08-0888.

Download references

Acknowledgments

This work is supported in part by grants from the National Natural Science Foundation of China (No. 81272776 and No. 81272419), China Postdoctoral Science Foundation (No. 20100471628 and No. 201104634), Wu Jieping Medical Foundation (320.6750.12161), Shaanxi Province Programs of Science and Technology Development (No. 2012 K 13-01-13 and 2011 K12-47), the Innovation Project 2012, and the Talents Program 2010 & 2013 of Tangdu Hospital, Fourth Military Medical University. We thank all the clinicians and hospital staff for help in the collection of samples and data for this study. Additionally, we thank Prof. Dr. Qing Li, Department of Pathology, Fourth Military Medical University, and Prof. Dr. Xue-jun Yang, Department of Pathology of General Hospital, Tianjin Medical University, for sharing their experiences with primary CNS tumors.

Author information

Author notes

    Affiliations

    1. Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi’an, 710038, P.R China

      • Gang Li
      • , Zhiguo Zhang
      • , Jianghong Zhang
      • , Hongjuan Liang
      • , Haixia Yang
      • , Shiming He
      •  & Guodong Gao

    2. National Engineering Research Center for Miniaturized Detection Systems, School of Life Sciences, Northwest University, Xi’an, 710069, P.R China

      • Tianbo Jin

    3. Department of Pathology, Tangdu Hospital, Fourth Military Medical University, Xi’an, 710038, P.R China

      • Li Gong

    4. Department of Radiology, Tangdu Hospital, Fourth Military Medical University, Xi’an, 710038, P.R China

      • Guangbin Cui

    5. Department of Administrative, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, P.R. China

      • Yongsheng Zhang

    Authors

    1. Search for Gang Li in:

    2. Search for Zhiguo Zhang in:

    3. Search for Jianghong Zhang in:

    4. Search for Tianbo Jin in:

    5. Search for Hongjuan Liang in:

    6. Search for Li Gong in:

    7. Search for Guangbin Cui in:

    8. Search for Haixia Yang in:

    9. Search for Shiming He in:

    10. Search for Yongsheng Zhang in:

    11. Search for Guodong Gao in:

    Corresponding authors

    Correspondence to Yongsheng Zhang or Guodong Gao.

    Additional information

    Competing interests

    The authors declare that they have no competing interest.

    Authors’ contributions

    YZ and GG designed the study. GL, ZZ, SH and GC participated in designing and coordinating the study, and GL drafted the manuscript. ZZ and TJ worked together to draft the manuscript. JZ, HL, LG and HY participated in following up the patient, reviewing the relevant articles, and helped to improve the manuscript. All authors have read and approved the final manuscript.

    Gang Li, Zhiguo Zhang, Jianghong Zhang contributed equally to this work.

    Authors’ original submitted files for images

    Authors’ original file for figure 1

    Authors’ original file for figure 2

    Authors’ original file for figure 3

    Authors’ original file for figure 4

    Authors’ original file for figure 5

    Authors’ original file for figure 6

    Authors’ original file for figure 7

    Authors’ original file for figure 8

    Authors’ original file for figure 9

    Rights and permissions

    Reprints and Permissions

    About this article

    Keywords

    • Oligodendroglioma
    • Extracranial metastasis
    • Autopsy
    • 1p/19q
    • Chromosome deletions
    • Genetic analysis

    Diagnostic Pathology

    ISSN: 1746-1596

    Contact us